Scientists test new Two-Part HIV vaccine strategy
NCT ID NCT05471076
Summary
This early-stage study is testing the safety and immune response of two different HIV vaccine regimens in healthy adults without HIV. The research aims to see if a new two-part vaccination approach can train the body's immune system to produce antibodies that could potentially block many strains of HIV. This is a Phase 1 trial primarily focused on safety, involving 52 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1 INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Alabama CRS
Birmingham, Alabama, 35222, United States
-
Bridge HIV CRS
San Francisco, California, 94102, United States
-
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
Boston, Massachusetts, 02115-6110, United States
-
Columbia P&S CRS
New York, New York, 10032, United States
-
Seattle Vaccine and Prevention CRS
Seattle, Washington, 98104, United States
-
The Ponce de Leon Center CRS
Atlanta, Georgia, 30308-2012, United States
Conditions
Explore the condition pages connected to this study.